臨床腫瘍学次世代シーケンスの世界市場レポート 2024年

2023年の臨床腫瘍学次世代シーケンサー市場で最大の地域は北米でした。アジア太平洋は臨床腫瘍学次世代シーケンス市場において2番目に大きい地域でした。臨床腫瘍学次世代シーケンス市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 臨床腫瘍学次世代シーケンス市場の特徴

第3章 臨床腫瘍学次世代シーケンス市場の動向と戦略

第4章 臨床腫瘍学次世代シーケンス市場-マクロ経済シナリオ

• 高インフレが臨床腫瘍学次世代シーケンス市場に与える影響
• ウクライナ・ロシア戦争が臨床腫瘍学次世代シーケンス市場に与える影響
• COVID-19による臨床腫瘍学次世代シーケンス市場への影響

第5章 世界の臨床腫瘍学次世代シーケンス市場規模と成長

• 世界の臨床腫瘍学次世代シーケンス市場の促進要因と抑制要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界の臨床腫瘍学次世代シーケンスの市場規模実績と成長、2018～2023年
• 世界の臨床腫瘍学次世代シーケンス市場規模と成長予測、2023～2028年、2033年

第6章 臨床腫瘍学次世代シーケンス市場セグメンテーション

• 世界の臨床腫瘍学次世代シーケンス市場、技術別セグメンテーション、実績および予測、2018～2023年、2023～2028年、2033年
• イオン半導体シーケンス
• パイロシーケンス
• 合成シーケンス
• リアルタイムシーケンス
• ライゲーションシーケンス
• 可逆的色素終結シーケンス
• ナノポアシーケンス
• 世界の臨床腫瘍学次世代シーケンス市場、用途別セグメンテーション、実績および予測、2018～2023年、2023～2028年、2033年
• スクリーニング
• コンパニオン診断
• その他の診断
• 世界の臨床腫瘍学次世代シーケンス市場、エンドユーザー別セグメンテーション、実績および予測、2018～2023年、2023～2028年、2033年
• 病院検査室
• 臨床研究機関
• 診断研究所

第7章 臨床腫瘍学次世代シーケンス市場の地域および国分析

• 世界の臨床腫瘍学次世代シーケンス市場、地域別、実績および予測、2018～2023年、2023～2028年、2033年
• 世界の臨床腫瘍学次世代シーケンス市場、国別、実績および予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋の臨床腫瘍学次世代シーケンス市場

第9章 中国の臨床腫瘍学次世代シーケンス市場

第10章 インドの臨床腫瘍学次世代シーケンス市場

第11章 日本の臨床腫瘍学次世代シーケンス市場

第12章 オーストラリアの臨床腫瘍学次世代シーケンス市場

第13章 インドネシアの臨床腫瘍学次世代シーケンス市場

第14章 韓国の臨床腫瘍学次世代シーケンス市場

第15章 西欧の臨床腫瘍学次世代シーケンス市場

第16章 英国の臨床腫瘍学次世代シーケンス市場

第17章 ドイツの臨床腫瘍学次世代シーケンス市場

第18章 フランスの臨床腫瘍学次世代シーケンス市場

第19章 イタリアの臨床腫瘍学次世代シーケンス市場

第20章 スペインの臨床腫瘍学次世代シーケンス市場

第21章 東欧の臨床腫瘍学次世代シーケンス市場

第22章 ロシアの臨床腫瘍学次世代シーケンス市場

第23章 北米の臨床腫瘍学次世代シーケンス市場

第24章 米国の臨床腫瘍学次世代シーケンス市場

第25章 カナダの臨床腫瘍学次世代シーケンス市場

第26章 南米の臨床腫瘍学次世代シーケンス市場

第27章 ブラジルの臨床腫瘍学次世代シーケンス市場

第28章 中東の臨床腫瘍学次世代シーケンス市場

第29章 アフリカの臨床腫瘍学次世代シーケンス市場

第30章 臨床腫瘍学次世代シーケンス市場の競合情勢と企業プロファイル

• 臨床腫瘍学次世代シーケンス市場の競合情勢
• 臨床腫瘍学次世代シーケンス市場の企業プロファイル
  • Thermo Fisher Scientific
  • Oxford Nanopore Technologies Ltd.
  • QIAGEN NV
  • Myriad Genetics Inc.
  • Illumina Inc

第31章 世界の臨床腫瘍学次世代シーケンス市場の競合ベンチマーキング

第32章 世界の臨床腫瘍学次世代シーケンス市場競合ダッシュボード

第33章 臨床腫瘍学次世代シーケンス市場における主要な合併と買収

第34章 臨床腫瘍学次世代シーケンス市場の将来展望と可能性分析

第35章 付録

“Clinical Oncology Next Generation Sequencing Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on clinical oncology next generation sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for clinical oncology next generation sequencing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The clinical oncology next generation sequencing market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Technology: Ion Semiconductor Sequencing; Pyro-Sequencing; Synthesis Sequencing; Real Time Sequencing; Ligation Sequencing; Reversible Dye Termination Sequencing; Nano-Pore Sequencing
• 2) By Application: Screening; Companion Diagnostics; Other Diagnostics
• 3) By End User: Hospital Laboratories; Clinical Research Organizations; Diagnostic laboratories
• Companies Mentioned: Thermo Fisher Scientific; Oxford Nanopore Technologies Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; Illumina Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Next generation sequencing (NGS) is a method employed to determine the sequence of nucleotides within a segment of DNA and is commonly utilized in oncology research. NGS plays a crucial role in identifying rare cancer mutations, detecting carriers of familial cancer mutations, and providing the molecular basis for targeted therapy.

The primary technologies in clinical oncology NGS encompass ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a sequencing technique based on the detection of hydrogen ions released during DNA polymerization. Clinical oncology NGS finds applications in various areas, including screening, companion diagnostics, and other diagnostic purposes, and it is used by a range of end-users, including hospital laboratories, clinical research organizations, and diagnostic laboratories.

The clinical oncology next-generation sequencing market research report is one of a series of new reports from The Business Research Company that provides clinical oncology next-generation sequencing market statistics, including clinical oncology next-generation sequencing industry global market size, regional shares, competitors with a clinical oncology next-generation sequencing market share, detailed clinical oncology next-generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next-generation sequencing industry. This clinical oncology next-generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.45 billion in 2023 to $0.52 billion in 2024 at a compound annual growth rate (CAGR) of 15.5%. The growth observed during the historical period can be attributed to advancements in genomic research, the discovery of cancer biomarkers, technological progress, and regulatory approvals.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. The anticipated growth in the forecast period can be attributed to factors such as the increasing incidence of cancer, the emergence of precision medicine, the advancements in immuno-oncology, and the adoption of liquid biopsies. Key trends expected in the forecast period encompass comprehensive genomic profiling (CGP), developments in immuno-oncology, the study of tumor evolution and heterogeneity, and the integration of AI and machine learning in oncology research.

The increasing number of cancer cases worldwide is expected to be a contributing factor to the growth of the clinical oncology next-generation sequencing market in the foreseeable future. In 2021, the USA alone reported 1.9 million new cancer cases and 0.6 million cancer-related deaths, according to data from the American Cancer Society. The most common cancer types globally include lung, prostate, colorectal, and breast cancer, accounting for 43% of all new cancer cases. Consequently, the rising global incidence of cancer is likely to drive demand and foster growth in the clinical oncology next-generation sequencing market.

The growing prevalence of cancer is projected to serve as a catalyst for the expansion of the clinical oncology next-generation sequencing market. Cancer is an umbrella term for a group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells within the body. Next-generation sequencing (NGS) plays a crucial role in identifying novel and rare mutations in cancer, enabling a deeper understanding of the molecular basis of individual tumors. For instance, data from the American Cancer Society in 2021 indicated that there would be an estimated 608,570 cancer-related deaths and 1.9 million new cancer cases diagnosed in that year. Thus, the increasing prevalence of cancer is a key driver of growth in the clinical oncology next-generation sequencing market.

The high costs associated with clinical oncology next-generation sequencing present a significant challenge for patients worldwide. There is a pervasive need to control expenses and demonstrate the value of healthcare services. Ongoing political uncertainties and economic pressures in many countries raise questions about the sustainability of public healthcare funding. In low-income nations, the absence of cost-effective cancer therapies has a substantial impact on the health and life expectancy of the population. An article published in 2020 by Genetics in Medicine reported genome sequencing costs of around £6,841 per cancer case and approximately £7,050 per rare disease case. The primary cost factors are the consumables required in the sequencing process, and equipment costs for rare cancer diseases are higher than those for common cancers. These factors restrain the growth of the market.

Companies in the clinical oncology next-generation sequencing market are increasingly investing in workflow automation to enhance precision and reduce sample-to-sample variability. For example, Agilent automation solutions have developed an automated system that enables a higher number of parallel reactions, reduces sample processing time, increases the volume of processed samples, and minimizes variability between samples. Additionally, companies like Sophia Genetics are focusing on data-driven medicine and the automation of DNA sequencing to enhance diagnostic and treatment capabilities.

Major companies operating in the clinical oncology next-generation sequencing market are introducing innovative products like the BenchMark ULTRA PLUS system to enhance their market competitiveness. The BenchMark ULTRA PLUS System is a valuable tool for clinical laboratories, particularly those involved in cancer diagnostics and research, as it ensures the accuracy and efficiency of diagnostic tests, ultimately contributing to improved patient care. For example, in June 2022, the Switzerland-based pharmaceutical company Roche unveiled the BenchMark ULTRA PLUS system, their state-of-the-art platform for tissue staining. This system provides clinicians with rapid and accurate test results, aiding in timely treatment decisions for patients.

In April 2021, Agilent Technologies, a US-based life sciences technology company, acquired Resolution Bioscience for an undisclosed amount, which expanded Agilent's capabilities in next-generation sequencing for cancer diagnostics. Resolution Bioscience is a US-based developer of precision oncology solutions based on next-generation sequencing (NGS).

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Clinical Oncology Next Generation Sequencing Market Characteristics

3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies

4. Clinical Oncology Next Generation Sequencing Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Clinical Oncology Next Generation Sequencing Market Size and Growth

• 5.1. Global Clinical Oncology Next Generation Sequencing Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Clinical Oncology Next Generation Sequencing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Clinical Oncology Next Generation Sequencing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Clinical Oncology Next Generation Sequencing Market Segmentation

• 6.1. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Ion Semiconductor Sequencing
• Pyro-Sequencing
• Synthesis Sequencing
• Real Time Sequencing
• Ligation Sequencing
• Reversible Dye Termination Sequencing
• Nano-Pore Sequencing
• 6.2. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Screening
• Companion Diagnostics
• Other Diagnostics
• 6.3. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Laboratories
• Clinical Research Organizations
• Diagnostic Laboratories

7. Clinical Oncology Next Generation Sequencing Market Regional And Country Analysis

• 7.1. Global Clinical Oncology Next Generation Sequencing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Clinical Oncology Next Generation Sequencing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Clinical Oncology Next Generation Sequencing Market

• 8.1. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Clinical Oncology Next Generation Sequencing Market

• 9.1. China Clinical Oncology Next Generation Sequencing Market Overview
• 9.2. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Clinical Oncology Next Generation Sequencing Market

• 10.1. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Clinical Oncology Next Generation Sequencing Market

• 11.1. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.2. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Clinical Oncology Next Generation Sequencing Market

• 12.1. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Clinical Oncology Next Generation Sequencing Market

• 13.1. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Clinical Oncology Next Generation Sequencing Market

• 14.1. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.2. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Clinical Oncology Next Generation Sequencing Market

• 15.1. Western Europe Clinical Oncology Next Generation Sequencing Market Overview
• 15.2. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Clinical Oncology Next Generation Sequencing Market

• 16.1. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Clinical Oncology Next Generation Sequencing Market

• 17.1. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Clinical Oncology Next Generation Sequencing Market

• 18.5. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Clinical Oncology Next Generation Sequencing Market

• 19.9. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Clinical Oncology Next Generation Sequencing Market

• 20.13. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Clinical Oncology Next Generation Sequencing Market

• 21.1. Eastern Europe Clinical Oncology Next Generation Sequencing Market Overview
• 21.2. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Clinical Oncology Next Generation Sequencing Market

• 22.1. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Clinical Oncology Next Generation Sequencing Market

• 23.1. North America Clinical Oncology Next Generation Sequencing Market Overview
• 23.2. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Clinical Oncology Next Generation Sequencing Market

• 24.1. USA Clinical Oncology Next Generation Sequencing Market Overview
• 24.2. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Clinical Oncology Next Generation Sequencing Market

• 25.1. Canada Clinical Oncology Next Generation Sequencing Market Overview
• 25.2. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Clinical Oncology Next Generation Sequencing Market

• 26.1. South America Clinical Oncology Next Generation Sequencing Market Overview
• 26.2. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Clinical Oncology Next Generation Sequencing Market

• 27.1. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Clinical Oncology Next Generation Sequencing Market

• 28.1. Middle East Clinical Oncology Next Generation Sequencing Market Overview
• 28.2. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Clinical Oncology Next Generation Sequencing Market

• 29.1. Africa Clinical Oncology Next Generation Sequencing Market Overview
• 29.2. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Company Profiles

• 30.1. Clinical Oncology Next Generation Sequencing Market Competitive Landscape
• 30.2. Clinical Oncology Next Generation Sequencing Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Oxford Nanopore Technologies Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. QIAGEN N.V.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Myriad Genetics Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Illumina Inc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Clinical Oncology Next Generation Sequencing Market Competitive Benchmarking

32. Global Clinical Oncology Next Generation Sequencing Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Clinical Oncology Next Generation Sequencing Market

34. Clinical Oncology Next Generation Sequencing Market Future Outlook and Potential Analysis

• 34.1 Clinical Oncology Next Generation Sequencing Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Clinical Oncology Next Generation Sequencing Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Clinical Oncology Next Generation Sequencing Market In 2028 - Growth Strategies
• 34.3.1 Market Trend Based Strategies
• 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer